Indication CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).

Other Treatment Options

CINRYZE Dosing and Administration1

CINRYZE for prevention of HAE attacks can be self-administered by the patient or administered by a caregiver or a healthcare provider. Talk with your patient and/or their caregiver to determine what administration option will work best for them.


Dosing of CINRYZE
 
  Adults and teenagers (≥12 years)1 Children (6 to 11 years)1
Dose
1,000 IU intravenous
For patients 12 years and older who have not responded adequately to lower doses, the highest dose will be 2000 IU (not to exceed 80 IU/kg). While each dose will contain a 20% increase in C1-INH activity based on the change in reference standard, the new maximum dose (i.e. 2000 IU, corresponding to 2400 U) has been adjusted to not exceed the maximum dose tested in clinical studies (2500 U).
500 IU intravenous
The dose may be adjusted according to individual response, up to 1,000 IU
Dosing regimen Administered every 3 or 4 days
Infusion rate 1 mL/min (10 minutes) 1 mL/min (5 minutes)

The Mix2Vial® transfer device is a needle-free reconstitution and transfer system to facilitate reconstitution and administration.

Would you like a copy of the CINRYZE preparation and self-administration guide for your patients?

Download PDF

Preparation and handling

  • CINRYZE should not be frozen, and it should be stored in its original carton to protect the active ingredient from light
  • Once reconstituted, the solution must be used within 3 hours
  • As supplied, CINRYZE is stable for the period stated on the vial and carton label at 2°C to 25°C (36°F to 77°F); check the expiration date prior to reconstitution

Keep patients on track

As you work with your HAE patients to create individualized treatment plans, you can help support compliance with CINRYZE. Consider the following approach:

  • Set up a treatment schedule to keep patients on track
  • Empower your patients to take charge by following the infusion schedule you provide
  • Remind patients about the benefits of staying compliant. Even if they are experiencing fewer or no attacks, missing a dose of CINRYZE can result in breakthrough attacks

Help patients stay on track with self-administration training.

Explore the program

You might also be interested in:

Dosing and Administration Safety Profile

Reference

  1. CINRYZE® (C1 esterase inhibitor [human]) Prescribing Information. Shire.

Definition: